MarketLine Blog

Posts tagged to Pharmaceutical

Overcrowded Unlicensed Medicines Industry: The NHS wins but smaller wholesalers lose

MarketLine

Unlicensed medicines, medicines which are not licensed in the UK, are becoming more popular. The market is growing due to the increasing demand for medicines which are not available on the NHS. These medicines may be too expensive or not in enough demand to justify bringing them in; the medicines may also not have the correct UK licensing to allow them to be sold in the country. There is also the potential problem with the supply chain which can result in a medicine being taken off the market temporarily and… Read more

Pfizer and AstraZeneca: merger of majors cancelled or just postponed?

MarketLine

Pfizer is currently the world’s largest research-based pharmaceutical company, with 2013 revenues (excluding consumer health) of $47.9 billion. Recently, it made a bid for the UK’s AstraZeneca (2013 revenues of $25.7 billion) equivalent to £50 ($78) per share. This valued the company at more than £63 billion ($98 billion). A lot of money, you might think, but AstraZeneca lost no time in rejecting the offer. The same thing happened back in January this year, when the American company valued AstraZeneca at around £59 billion. Its CEO commented of the latest… Read more